Press releases

Results of General Meeting

Oxford, UK – 6 January 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, announced the results of its General Meeting held today in London.  In accordance with Listing Rule 9.6.18, the following resolution was passed at the meeting:

Resolution 1: THAT, the entry by the Company into the proposed secured Loan Facility of up to £5 million with Vulpes Life Sciences Fund, being a related party transaction for the purposes of the Listing Rules, be and is hereby approved.

The full text of the Shareholder Circular and the Notice of Meeting can be viewed by visiting the Company’s website at www.oxfordbiomedica.co.uk.

Certified copies of the document setting out the above resolution passed at this General Meeting have been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.Hemscott.com/nsm.do.

The results of the proxy voting in advance of the meeting are shown below.

Resolution

1

Votes for

331,276,628

Votes at Chairman’s discretion

1,016,145

Votes at other proxy discretion

981,574

Votes against

718,232

Votes withheld

716,075

Total votes cast

334,708,654

Result

Approved

-Ends

Notes to editors

About Oxford BioMedica®

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery platform (LentiVector®) through which the Group develops in vivo and ex-vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk.

For further information please contact

Oxford BioMedica plc

John Dawson, Chief Executive Officer

Stuart Paynter, Chief Financial Officer

Tel: +44 (0)1865 783 000

 

Consilium Strategic Communications – Media Enquiries

Mary-Jane Elliott/Matthew Neal/Philippa Gardner/Laura Thornton/Rosie Phillips

Tel: +44 (0)20 3709 5700